Video Presentation

VIDEO: Open Orphan’s Cathal Friel on pharma services firm’s plans and COVID-19 work (piworld) (ORPH)

17 Mar 2020 | by: Richard Mason

Open Orphan (LSE:ORPH) is a rapidly-growing pharmaceutical services company with a focus on rare and orphan drugs.

Following its reverse takeover of hVIVO earlier this year, it has also become a world-leader in the provision of virology and vaccine challenge study services and viral laboratory services.

In the video below, provided by piworld, executive chairman Cathal Friel talks through what the firm does, the long-term opportunity it presents for investors, and its ongoing support work for companies developing coronavirus vaccinations.

piworld provides content for investors, by investors.

The organisation aims to help private investors get closer to companies and their management and – in turn – make more informed investment decisions.

Videos include:

•             Company results presentations

•             Management interviews

•             Company visits

•             Enlightened educational investor videos with investors, opinion formers, and industry leaders, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

  • Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.
  • Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

More News & Analysis